SCHEMBL7143282

SCHEMBL7143282

[c]1oc(-c2ccc3ccccc3n2)c2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 0.44
RAB9A P51151 11/20 0.42
NPC1 O15118 10/20 0.42
ALDH1A1 P00352 8/20 0.42
HSD17B10 Q99714 4/20 0.42
PKM P14618 4/20 0.42
HPGD P15428 4/20 0.42
MAPT P10636 4/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
TP53 P04637 3/20 0.42
HCRTR1 O43613 1/20 0.42
CYP3A4 P08684 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KDM4E B2RXH2 9/20 0.39
SMN1; SMN2 Q16637 6/20 0.39
PMP22 Q01453 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3835162 0.71 RAB9A (0.50) ARRAB9ANPC1ALDH1A1HSD17B10
SCHEMBL7686040 0.70 ALDH1A1 (0.49) RAB9ANPC1ALDH1A1HSD17B10PKM
SCHEMBL170196 0.70 RAB9A (0.64) ARRAB9ANPC1ALDH1A1HSD17B10
SCHEMBL29374931 0.70 RAB9A (0.64) ARRAB9ANPC1ALDH1A1HSD17B10
SCHEMBL4875157 0.69 RAB9A (0.46) ARRAB9ANPC1ALDH1A1HSD17B10
SCHEMBL10866984 0.68 RAB9A (0.61) ARRAB9ANPC1ALDH1A1HSD17B10
SCHEMBL31490600 0.68 RAB9A (0.61) ARRAB9ANPC1ALDH1A1HSD17B10
SCHEMBL30883993 0.68 RAB9A (0.61) ARRAB9ANPC1ALDH1A1HSD17B10
SCHEMBL31365172 0.68 RAB9A (0.61) ARRAB9ANPC1ALDH1A1HSD17B10
SCHEMBL34463709 0.68 RAB9A (0.61) ARRAB9ANPC1ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US claimed
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US disclosed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP disclosed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO disclosed